Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P090016/S066

Belotero Balance (+) Lidocaine Dermal Filler

Merz North America, Inc. · Decision date Oct 10, 2025

FDA DECISIONP090016/S066

What did the FDA approve?

FDA records P090016/S066 as a supplement to PMA P090016, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Oct 10, 2025.

FDA approval order statement

approval for a change to the release and shelf-life specifications for Belotero Balance (+) Lidocaine Dermal Filler
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
General, Plastic Surgery
Decision date
Oct 10, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P090016/S066
Regulatory pathway
PMA supplement
Product code
LMH
Decision code
APPR
Decision date
Oct 10, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P090016/S066 received

    Application receipt date recorded by FDA.

  2. P090016/S066 · FDA decision

    Normal 180 Day Track

  3. P090016/S068 · Related supplement

    Belotero Balance (+) Lidocaine Dermal Filler

  4. P090016/S067 · Related supplement

    Belotero Balance Dermal Filler; Belotero Balance (+) Lidocaine

Timeline entries are records held by MedtechLedger for P090016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P090016

Product / regulatory recordCompanyPathwayDecision dateSource
Merz North America, Inc.PMA supplementOct 24, 2025FDA
Merz North America, Inc.PMA supplementMay 3, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Merz North America, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4133 Ct.ney Rd., Suite 10, Franksville, WI, 53126

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records